ESR1 and triple-negative breast carcinoma: Interestingly, clinical trials have demonstrated higher response rates to immune checkpoint blockade in triple-negative breast cancer (TNBC) tumors when compared with estrogen-receptor positive (ER+) tumors, allowing for potential discrimination [29,30,31].